NOAC Portuguese Real World Study

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

NCT03563937 ·Status: COMPLETED

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767 ·Status: COMPLETED ·Phase: PHASE3

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

NCT03189069 ·Status: COMPLETED

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots

NCT03537521 ·Status: WITHDRAWN

Rivaroxaban for Patients With Antiphospholipid Syndrome

NCT02926170 ·Status: COMPLETED ·Phase: PHASE3

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

NCT02792335 ·Status: COMPLETED

Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19

NCT04416048 ·Status: TERMINATED ·Phase: PHASE2

A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin

NCT05051904 ·Status: COMPLETED

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

NCT04878497 ·Status: UNKNOWN

Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

NCT04263038 ·Status: RECRUITING ·Phase: PHASE4

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

NCT05038228 ·Status: ACTIVE_NOT_RECRUITING

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

NCT02468102 ·Status: COMPLETED

Anticoagulation Preference by AF Patients Study

NCT02607371 ·Status: COMPLETED

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

NCT04297150 ·Status: UNKNOWN

Rivaroxaban in Thrombotic Antiphospholipid Syndrome

NCT02157272 ·Status: TERMINATED ·Phase: PHASE3

Evaluataion of NOAC Levels in Acute Stroke

NCT06144866 ·Status: RECRUITING

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647 ·Status: COMPLETED ·Phase: PHASE3

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

NCT02687867 ·Status: COMPLETED

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over

NCT02286414 ·Status: COMPLETED

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

NCT01947998 ·Status: COMPLETED

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

NCT02470767 ·Status: COMPLETED

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155 ·Status: COMPLETED

Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation

NCT06862726 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4

Reversal of the Antithrombotic Action of New Oral Anticoagulants

NCT01478282 ·Status: UNKNOWN ·Phase: PHASE4

Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects

NCT05491460 ·Status: UNKNOWN ·Phase: PHASE1